{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
OptimizeRx Corp.
OptimizeRx Corp. Hits New 52-Week High of $20.66, Up 79.82%
OptimizeRx Corp. has achieved a new 52-week high, reflecting a significant performance improvement over the past year. The company, with a market capitalization of USD 340 million, operates in a competitive sector and maintains a low debt-to-equity ratio, despite being a loss-making entity.
OptimizeRx Corp. Hits New 52-Week High of $19.47, Up 67.19% Year-Over-Year
OptimizeRx Corp. achieved a new 52-week high of USD 19.47 on September 23, 2025, reflecting strong performance in the software products industry. The company has seen significant growth over the past year, despite being unprofitable, and maintains a low debt-to-equity ratio, indicating financial stability.
Is OptimizeRx Corp. technically bullish or bearish?
As of September 12, 2025, OptimizeRx Corp. has a mildly bullish technical trend, supported by bullish MACD and Bollinger Bands, despite mixed signals from KST and Dow Theory, and it has significantly outperformed the S&P 500 year-to-date with a return of 289.30%.
Is OptimizeRx Corp. overvalued or undervalued?
As of May 4, 2022, OptimizeRx Corp. is considered overvalued with a risky valuation grade due to negative valuation ratios, including an EV to EBIT of -86.78 and a high EV to EBITDA of 271.52, despite a strong year-to-date stock performance of 289.30%.
Is OptimizeRx Corp. overvalued or undervalued?
As of May 4, 2022, OptimizeRx Corp. is considered risky and overvalued due to negative earnings and high valuation ratios, despite a strong stock return of 167.08% year-to-date, which is not justified by its financial metrics.
Is OptimizeRx Corp. technically bullish or bearish?
As of May 13, 2025, the market trend is bullish, supported by strong indicators like a bullish MACD, moving averages, and Bollinger Bands, despite a mildly bearish signal from Dow Theory on the weekly chart.
Who are in the management team of OptimizeRx Corp.?
As of March 2022, the management team of OptimizeRx Corp. includes Chairman Gus Halas, CEO William Febbo, and Directors Gregory Wasson, James Lang, Patrick Spangler, and Lynn Vos. They oversee the company's strategic direction and operations.
What does OptimizeRx Corp. do?
OptimizeRx Corporation is a digital health company that enhances communication among healthcare stakeholders at the point-of-care. As of March 2025, it reported net sales of $22 million and a market cap of $247.83 million, but is currently operating at a loss.
How big is OptimizeRx Corp.?
As of Jun 18, OptimizeRx Corp. has a market capitalization of 247.83 million and reported net sales of 94.37 million with a net profit of -15.41 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
